HomeHealth articlesmonoclonal antibodiesWhat Is a Monoclonal Antibody Cocktail?

Monoclonal Antibodies: Casirivimab and Imdevimab

Verified dataVerified data
0

4 min read

Share

Amidst the emerging third wave of COVID, researchers suggest using monoclonal antibodies-Casirimivab and Imdevimab in comorbid patients.

Medically reviewed by

Dr. Infanteena Marily F.

Published At October 16, 2021
Reviewed AtAugust 9, 2023

Introduction

The mAb, which has now received emergency use authorization in India by the central drug standards control, is the cocktail drug of monoclonal antibodies, Casirivimab and Imdevimab. It also has gained approval in the United States and other European countries. Developed by Roche India and Cipla, antibody cocktails Casirimivab and Imdevimab act directly on the spike protein of the viral genome of the SARS COV-2 virus. This authorization makes it easier for reducing the hospitalization risk of COVID-19 patients who are at high risk and prone to developing severe COVID symptoms:

It is valuable for older adults above the age of 55-60 years, with type 1 or type 2 diabetes, chronic kidney diseases, hypertension, cardiovascular disease, chronic pulmonary obstructive disease, Immunosuppressive disorders, cancers, chronic liver disease, and asthma. Also, individuals with neurodevelopmental or congenital conditions between the ages of 12 to 17 who are prone to COVID infection, obese individuals with a high BMI >35 can be benefitted from this treatment.

Structure of SARS COV-2 Genome:

The deadly SARS COV-2 genome mainly comprises or encodes four major structural proteins along with accessory proteins and non-structural proteins. The four significant proteins encoded by the viral genome are

1. Spike (S)- Further divided into two subunits S1 and S2 (for invasion and host cell attachment):

i). S1- It has a receptor-binding domain (RBD) that attaches to the ACE 2 host cell receptors (Angiotensin-converting enzyme receptors).

ii). S2- Post binding to the receptors, the S2 subunit manipulates or initiates the viral entry into the host cells apart from membrane fusion as it structurally or conformationally changes as soon as the S1 begins cell binding.

2. Envelope (E).

3. Membrane (M).

4. Nucleocapsid (N).

Mainly, the spike protein that is responsible for mediating host cell attachment and invasion is the target of the monoclonal antibodies, which have been evidently proved to be clinically beneficial and acceptable by physicians.

What Is a Monoclonal Antibody Cocktail?

Casirivimab and Imdevimab are laboratory-made proteins (produced by recombinant DNA technology) or rather IgG1 (Immunoglobulin G-1) directed explicitly to the spike proteins S1 and S2 of SARS COV-2 antigen, thus blocking both the viral attachment as well as the replication in the host cells. They are administered after dilution by Intravenous infusion only after being prescribed by a highly qualified healthcare professional. These IV infusions of mAb’s typically take around 20-30 minutes for administration. However, both Casirivimab and Imdevimab are not authorized for use by physicians, especially in chronic comorbid patients who are hospitalized due to the infection or who require supportive oxygen therapy for COVID-19.

Patients treated with this antibody cocktail should continue to self-isolate and use precautions of necessary distancing, frequent handwashing, proper physical hygiene, and usage of face masks. Each pack of the antibody cocktail contains one vial that totals 2400 mg (1200 mg of Casirivimab and 1200 mg of Imdevimab). The dosage per patient is 1200 mg overall containing 600 mg of Casirivimab and 600 mg of Imdevimab.

Subcutaneous administration of the drug is also possible apart from IV infusion. For the subcutaneous route, four syringes of 2.5 ml (2 each of Casirivimab and Imdevimab) are concurrently administered at four different sites on the abdomen or the thigh region. These antibody cocktail vials are usually stored between 2 degrees to 8 degrees Celsius. Patients are monitored both during the infusion and one hour after the injection by qualified healthcare providers or professionals in a clinical setting. It is done to make sure emergency access to medications are possible by the physician in the possibility of anaphylaxis.

How Do Monoclonal Antibodies Act?

Monoclonal antibody therapies are the only drugs proven efficacious apart from vaccines to treat and prevent COVID infection, especially in high-risk groups like unvaccinated or individuals with multiple comorbidities. These monoclonal antibodies don’t generate host immunity like vaccines. Instead, they have a mechanism of action where the viral antigen gets bound by these mAb’s, thus penetrating and eliminating them faster from the host immune system. A similar technique developed 35 years ago by scientists and researchers was most recently used against the Ebola virus outbreak. The primary reason why physicians are recommending mAb’s is that they are prophylactically effective in preventing the transmission of the SARS COV-2 virus within households.

The monoclonal antibody cocktails also have a longer duration acting potential. For example, AstraZeneca’s monoclonal cocktail uses a half-life extension technique YTE that increases the duration of therapeutic release of these antibodies beyond a specific time limit that makes this treatment potentially three times more durable than conventional antibodies. Research also shows an intramuscular injection of mAbs for immunocompromised cases and in high-risk frontline health workers and staff can last therapeutically in the host immune system for approximately a year.

Availability of mAb:

These monoclonal antibodies are not widely deployed for public use and are approved only for emergency administration by the FDA in the United States. It is used in mild to moderate COVID-19 patients who are non hospitalized and are at severe or high risk of infectious progression that may lead to hospitalization and emergency support. In the recent past, it was selectively administered only to high-profile patients suffering from the novel coronavirus in the United States. Also, it was given for recovered individuals from an active COVID-19 infection as a prophylactic regimen after viral exposure.

The limited and high-cost treatment of these mAbs can be attributed to the logistic difficulties and not the full-fledged nod from the FDA or the central governments to use it prophylactically in the general population. The general public may not be able to afford the high-cost treatment. In addition, its use is questionable due to the ten high production costs that already hamper the limited availability and decrease the extensive scale application of antibody-based therapies.

Against the newer delta variant and its mutations, researchers speculate the presence of monoclonal antibodies to act more effectively and for a longer duration than the COVID vaccine as these mAbs maintain a high defense level against mutating variants of the novel pathogen. One more drawback would be that in people receiving mAb’s, the COVID vaccination should be deferred by 90 days to prevent a vaccine-induced immune response.

What Are the Limitations of Monoclonal Antibodies, Casirivimab and Imdevimab?

  • The COVID-19 vaccine is not a replacement for post-exposure prophylaxis with mAb (Casirivimab and Imdevimab).

  • It is not permitted to use mAb (Casirivimab and Imdevimab) as pre-exposure prophylaxis to prevent COVID-19.

Conclusion:

Monoclonal antibody cocktail is highly efficacious in high-risk patients prone to coronavirus infection. It is currently being implemented for emergency treatment that would be combative against the emerging variants/strains of the SARS COV-2 pathogen. However, authorization, logistics, and limited supply are the main drawbacks of utilizing mAb’s in the general population.

Frequently Asked Questions

1.

How Long After Monoclonal Antibodies Should Be Quarantined?

According to CDC guidelines, patients should wait 90 days after monoclonal antibody infusion therapy. Based on the findings, patients who underwent these therapies nevertheless mounted a significant immune response to mRNA immunization soon after treatment. The importance of vaccination should be considered, and whenever possible, the second dose should be administered on time.

2.

What Are the Side Effects of Monoclonal Treatment for COVID?

The side effects of the monoclonal treatment for COVID include:
- Nausea.
- Vomiting.
- Diarrhea.
- Chills.
- Fever.
- Headache.
- Coughing or wheezing. 
- Reduction in blood pressure. 
- Skin swelling or inflammation. 
- Throat irritation. 
- Rash.
- Itching.
- Muscle pain or ache.

3.

Do Monoclonal Antibodies Work for Omicron?

Monoclonal antibodies are proteins produced in a lab that replicate the immune system's capability to defend against dangerous diseases such as viruses like SARS-CoV-2. In addition, SARS-CoV-2 can change over time, just like other contagious organisms, which makes some treatments ineffective against some variants like omicron.

4.

Is COVID Still Contagious After Monoclonal Antibodies?

COVID-19 cannot be cured by monoclonal antibody therapy. After obtaining mononucleosis treatment, the patient can spread the disease to others; therefore, patients must stay in quarantine for the first 10 days and maintain hydration.

5.

Will the Test Result be Positive After Monoclonal Antibodies?

The CDC states that the virus may remain in the body for at least 10 to 14 days. Therefore, it is possible to spread the condition if it is contagious. It is recommended that those who get monoclonal treatment wait at least 10 days in quarantine and stay hydrated.

6.

What Are the Disadvantages of Monoclonal Antibodies?

The disadvantages of monoclonal antibodies include:
- Time-consuming.
- Expensive.
 
 Side effects like: 
- Fever.
- Chills.
- Fatigue or weakness.
- Nausea. 
- Vomiting or diarrhea.
- Low blood pressure.
- Rash.
- Anaphylaxis.

7.

Can Monoclonal Antibodies Make It Worse?

Worsening symptoms following monoclonal antibodies may result in new or worsening symptoms following infusion, such as fever, breathing difficulties, irregular heartbeat, fatigue, numbness, or confusion.

8.

Why Wait 90 Days After Monoclonal Antibodies?

The CDC states that the virus may remain in the body for at least 10 to 14 days so that people may be able to spread the condition if they are contagious. It is recommended that those who get monoclonal treatment wait at least 10 days in quarantine and stay hydrated.

9.

Should I Get Monoclonal Antibodies if I Have COVID?

Treatment with monoclonal antibodies is most effective when started early; the earlier it is activated, the better. Treatment is ineffective for those who have COVID-19 and are already hospitalized or in critical condition. Monoclonal antibodies are not a substitute for immunization.

10.

How Long Does It Take for Monoclonal Antibodies to Work?

According to studies, monoclonal antibodies may work 24 to 48 hours after the infusion. So it is necessary to stay isolated after the infusion. The chances of spreading capacity are high, so stay hydrated.
Source Article IclonSourcesSource Article Arrow
Dr. Achanta Krishna Swaroop
Dr. Achanta Krishna Swaroop

Dentistry

Tags:

imdevimabcasirivimabmonoclonal antibodies
Community Banner Mobile
By subscribing, I agree to iCliniq's Terms & Privacy Policy.

Source Article ArrowMost popular articles

Do you have a question on

monoclonal antibodies

Ask a doctor online

*guaranteed answer within 4 hours

Disclaimer: No content published on this website is intended to be a substitute for professional medical diagnosis, advice or treatment by a trained physician. Seek advice from your physician or other qualified healthcare providers with questions you may have regarding your symptoms and medical condition for a complete medical diagnosis. Do not delay or disregard seeking professional medical advice because of something you have read on this website. Read our Editorial Process to know how we create content for health articles and queries.

This website uses cookies to ensure you get the best experience on our website. iCliniq privacy policy